Clinical Trials Logo

Hepatorenal Syndrome clinical trials

View clinical trials related to Hepatorenal Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02123576 Terminated - Clinical trials for Hepatorenal Syndrome

Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline

Start date: April 2014
Phase: N/A
Study type: Interventional

Pentoxyfylline therapy in addition to the standard of care of albumin, midodrine and octreotide therapy is superior to the standard of care alone in the treatment of Type I hepatorenal syndrome in the first 14 days of hospitalization.

NCT ID: NCT01906307 Terminated - Clinical trials for Hepatorenal Syndrome Type I and Type II

A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome

Start date: March 2014
Phase: Phase 1
Study type: Interventional

Hepatorenal syndrome (HRS) is a life-threatening condition marked by rapid decline in kidney function in patients with liver cirrhosis or fulminant liver failure. Vasodilation in the gastrointestinal region is largely thought to contribute to the disease. LJPC-501 is a vasoconstrictor that may restore proper circulation and kidney function in patients with HRS.

NCT ID: NCT00742339 Terminated - Cirrhosis Clinical Trials

Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Start date: May 2005
Phase: Phase 2/Phase 3
Study type: Interventional

From 1999, several studies have showed that the use of vasoconstrictors in association with albumin are effective in the treatment of hepatorenal syndrome (HRS). The rationale of the use of vasoconstrictors together with albumin in the treatment of this severe complication of portal hypertension in patients with cirrhosis is to correct the reduction of the effective circulating volume due to the splanchnic arterial vasodilatation.In most of these studies terlipressin, a derivate of vasopressin, has been used as vasoconstrictor as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr. In some studies midodrine, an alpha-adrenergic agonist, given by mouth has been used as vasoconstrictor at a dose ranging from 2.5 up to 12.5 tid together with octreotide, an inhibitor of the release of glucagon, given subcutaneously at a dose ranging from 10 µg upt to 200 µg tid. To the day, there isn't a study comparing terlipressin + albumin versus midodrine + octreotide + albumin in the treatment of HRS in patients with cirrhosis.Thus, the aim of the study is to compare terlipressin + albumin vs midodrine + octreotide + albumin in the treatment of the HRS in patients with cirrhosis.

NCT ID: NCT00734136 Terminated - Liver Diseases Clinical Trials

Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

Start date: May 2005
Phase: N/A
Study type: Interventional

This Study will look at the effect of substances called "angiogenic factors"(development of new blood vessels) have on the development of severe liver disease. The results may help to understand the factors involved in the repair and regeneration of liver tissue and to see if different types of liver disease are associated with different types of factors, especially in the severe liver disease called hepatorenal syndrome.